Login / Signup

A Phase I Trial of Oxaliplatin, Irinotecan, and S-1 Combination Therapy (OX-IRIS) as Chemotherapy for Unresectable Pancreatic Cancer (HGCSG 1403).

Yasuyuki KawamotoHiroshi NakatsumiKazuaki HaradaTetsuhito MuranakaAtsushi IshiguroYoshimitsu KobayashiHideyuki HayashiSatoshi YukiKentaro SawadaMasataka YagisawaShintaro NakanoNaoya SakamotoYoshito Komatsu
Published in: The oncologist (2021)
MTD of OX-IRIS therapy was estimated to be level 0, and the recommended dose (RD) for future trial was level -1.
Keyphrases
  • combination therapy
  • phase iii
  • study protocol
  • locally advanced
  • phase ii
  • clinical trial
  • randomized controlled trial
  • current status
  • open label
  • stem cells
  • rectal cancer
  • mesenchymal stem cells